NT-0796 Reduces Neuroinflammation in Parkinson's Phase Ib/IIa Trial

NodThera, a prominent biotech firm, has announced the successful results of a Phase Ib/IIa clinical trial for its NLRP3 inflammasome inhibitor, NT-0796, which is designed to treat chronic inflammatory diseases, including Parkinson's. The study showed that NT-0796 effectively reduced neuroinflammatory and inflammatory biomarkers in Parkinson's patients to levels comparable to those of healthy individuals within a 28-day period. This breakthrough suggests a potential paradigm shift in treating the disease by not only managing symptoms but also halting its progression, offering a disease-modifying approach.
The trial's positive outcomes, highlighting the drug's ability to reverse NLRP3-mediated neuroinflammation and decrease neurodegenerative markers, were set to be presented at the AD/PDTM 2024 conference in Lisbon, Portugal. NT-0796 was found to be safe, with mild and transient adverse events, and no serious adverse events reported. The drug's pharmacokinetics suggest suitability for once-daily administration, and its brain levels, as measured in cerebrospinal fluid, were sustained over 24 hours.
The study's findings indicate that NT-0796 could provide a long-term oral treatment option for Parkinson's patients, with anti-inflammatory effects observed within a week and maintained for the trial's duration. Notably, the drug's impact on reducing peripheral inflammation, as evidenced by significant decreases in CRP and fibrinogen levels, aligns with its previously observed effects in elderly volunteers.
Alan Watt, NodThera's CEO, expressed optimism about the drug's implications for Parkinson's disease treatment, emphasizing the correlation between the disease and neuroinflammation. He highlighted the drug's potential to address a broader spectrum of neurodegenerative diseases and the company's advanced planning for Phase II studies.
Prof. Thomas Foltynie, a neurology expert, lauded the results as promising for the future of Parkinson's treatment, noting the importance of modulating brain inflammation, a key factor in the disease's development. The study's success positions NT-0796 as a candidate for a transformative treatment that could potentially halt the disease's progression, offering significant value to patients.
NodThera's ongoing efforts also include a Phase Ib/IIa clinical study of NT-0796 in obese subjects with cardiovascular risk, with results expected by the end of the second quarter of 2024. This study is measuring changes in CRP levels and body weight over 28 days, further demonstrating the company's commitment to advancing treatments for chronic inflammatory conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!